Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dragonfly Achieves AbbVie Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Dragonfly Achieves AbbVie Milestone

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET to enter into clinical trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing immunotherapies, has received a milestone payment following dosing the first patient in a clinical trial conducted by AbbVie to evaluate ABBV-303, a solid tumor targeting TriNKET.
 
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly’s platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter the clinic. The Phase 1 trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie’s budigalimab (ABBV-181), in solid tumors.
 
“We are delighted that AbbVie has advanced ABBV-303 into the clinic,” said Bill Haney, CEO and Dragonfly co-founder. “AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics